Roche Reports Phase 3 SKYSCRAPER-02 Results for Tiragolumab in Small Cell Lung Cancer

Roche today announced results from the Phase 3 SKYSCRAPER-02 trial evaluating tiragolumab plus atezolizumab and chemotherapy versus atezolizumab and chemotherapy in patients with extensive-stage small cell lung cancer. While the trial did not meet its primary endpoints, the data provided insights into the role of TIGIT inhibition in SCLC.